No Early Effect of Intrathecal Rituximab in Progressive Multiple Sclerosis (EFFRITE Clinical Trial)

Table 2

Studies of intrathecal rituximab in progressive MS.

Ref.	(); ratio^a	EDSS baseline	Clinical/MRI activity (≤1year)	Rituximab protocol	Biomarkers
[8]	23; 1.5 : 1	6.5; 2.5-7.0	Yes	IT LP 25 mg ×2; IV 200 mg ×2	IgG index, NFL, CXCL13, CCL19, sCD14: unchanged; IL12p40 -42%, BAFF +8%, sCD21, sCD27: minimal changes.
[9]	23; 1 : 0	6.5; 4.0-7.5	No	IT Om. 25 mg ×3	NFL, GFAP, MBP, Gal-9, sCD27, CXCL14: unchanged; CXCL13: minimal decrease.
[10]	9; 1 : 0	5.5; 4.0-8.0	Yes	IT LP 5-10-15 mg	λ FLC, CXCL13: unchanged; κFLC: minimal increase; BAFF: decreased
[11]	8; 1 : 0	6.0	No	IT LP 25 mg ×2	NFL, sCD21, sCD27, sCD14, CCL19, CCL21: unchanged; BAFF increased; CXCL13: decreased.
Our	10; 4 : 1	6.5; 6.0-8.0	No	IT LP 20 mg; ±IV 375 mg/m^2 (1 : 1)	IgG index, OCB, NFL, OPN: unchanged.

IT: intrathecal; LP: lumbar puncture; Om.: Ommaya reservoir. ^aratio active : control.